Discovery and development of clinically useful biomarkers for Alzheimer's disease (AD) and
related dementias have been the focus of recent research efforts. While cerebrospinal fluid …

Background The panel of fluid-and imaging-based biomarkers available for
neurodegenerative disease research is growing and has the potential to close important …

Introduction Pre‐analytical sample handling might affect the results of Alzheimer's disease
blood‐based biomarkers. We empirically tested variations of common blood collection and …

Background Soluble amyloid-β (Aβ) oligomers are the major toxic substances associated
with the pathology of Alzheimer's disease (AD). The ability to measure Aβ oligomer levels in …

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, and the early
diagnosis of AD remains challenging. Here we have developed a fluorescent sensor array …

Background Because of high prevalence of Alzheimer's disease (AD) in low-and middle-
income countries (LMICs), there is an urgent need for inexpensive and minimally invasive …

Alzheimer's disease (AD) is the most-common cause of neurodegenerative dementia, and it
is characterized by abnormal amyloid and tau accumulation, which indicates …

Objective The objectives of this study were to investigate whether the plasma levels of
oligomeric amyloid-β (OAβ) were affected in Alzheimer's disease (AD) and to examine the …

New highly sensitive direct methods for the early detection of peptides involved in
Alzheimer's disease (AD) are required in order to prolong effective and healthy memory and …

The preclinical diagnosis and clinical practice for Alzheimer's disease (AD) based on liquid
biopsy have made great progress in recent years. As liquid biopsy is a fast, low-cost, and …